41 Quotes by Jan Wald

What the FDA seemed to be saying is that it doesn't know if Boston Scientific has a systemic, corporate-wide quality policy, and until it does the FDA will not permit the company to gain product approvals in adulterated plants.

Boston Scientific will do everything in its power to reach a deal with Guidant.

After all the noise they made, there would certainly be a lot of questions asked (if they raised their bid).

They might have passed the acid test of being too big.

There was nothing in the earnings report that would renew investor interest.

There's a lot of frustration among institutional shareholders and employees who own the stock.

It's less serious than I thought it was.

It's still a possibility. But the valuation is high, and one thing we learnt from the J&J bid for Guidant is they are very sensitive to valuation.

It's still a possibility. But the valuation is high, and one thing we learned from the J&J bid for Guidant is they are very sensitive to valuation.